Compare iShares MSCI China ETF (MCHI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI China ETF trades at $51.33 (market cap $5.82B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares MSCI China ETF is far larger — about 6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 65 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MCHI | MRVI | |
|---|---|---|
Market Cap | $5.82B | $977.37M |
Volume | 1,436,013 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $9.00 |
52-Week Low | $50.48 | $2.83 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $52.135, down 0.03% on the day with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support and resistance cluster tightly around $52, indicating consolidation near current levels with neutral oscillator readings.
MCHI presents a valuation opportunity trading at a significant discount to historical averages versus US indices, but risks include China's regulatory uncertainty, global trade friction, and weak domestic consumption. The upcoming Trump-Xi summit on September 24 could provide catalysts through potential trade agreements, though protectionism concerns remain elevated for Chinese equity exposure.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
